title: Cholesterol sulfate, a second messenger for the eta isoform of protein kinase C, inhibits promotional phase in mouse skin carcinogenesis.
abstract: Cholesterol sulfate is a second messenger for the eta isoform of protein kinase C mediating squamous differentiation. We found that cholesterol sulfate inhibited the promotional phase of skin carcinogenesis in female CD-1 mice, which was initiated by 100 micrograms 7,12-dimethylbenz[a]-anthracene and promoted by a single application of 10 micrograms 12-O-tetradecanoylphorbol-13-acetate, followed by repeated applications of 10 micrograms mezerein once a week for 19 weeks. Cholesterol sulfate, when applied topically at a dose of 400 micrograms (820 mumol) 10 min before treatment with the promoters, markedly suppressed tumor formation, resulting in decrease of 56% in the incidence of tumor-bearing mice, 81% in the number of tumors/mouse, and 60% in the size of tumors at 20 weeks of the promotion. This inhibition was not due to elimination of the initiated cells. Treatment with the parental cholesterol at a dose of 320 micrograms (820 mumol), which does not activate the eta isoform, did not inhibit tumor promotion. Repeated treatment with cholesterol sulfate induced scaling of skin at the site of application. Cholesterol sulfate, unlike most inhibitors of tumor promotion, did not inhibit induction of ornithine decarboxylase and hyperplasia in mouse epidermis caused by topical treatment with 12-O-tetradecanoylphorbol-13-acetate. These findings suggest that cholesterol sulfate inhibits tumor promotion by stimulating a differentiation pathway mediated by the eta isoform of protein kinase C.
authors.affiliation: Department of Cancer Cell Research, University of Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Chida
authors.forename: A
authors.initials: A
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Tagawa
authors.forename: T
authors.initials: T
authors.lastname: Ikuta
authors.forename: T
authors.initials: T
authors.lastname: Kuroki
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D002273:Carcinogens; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002788:Cholesterol Esters / Q000627:therapeutic use*; D004789:Enzyme Activation; D004790:Enzyme Induction; D005260:Female; D006965:Hyperplasia / Q000517:prevention & control; D007527:Isoenzymes / Q000378:metabolism*; D051379:Mice; D008815:Mice, Inbred Strains; D009955:Ornithine Decarboxylase / Q000096:biosynthesis; D011493:Protein Kinase C / Q000378:metabolism*; D015290:Second Messenger Systems / Q000502:physiology*; D012867:Skin / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D013755:Tetradecanoylphorbol Acetate
chemical_list: D016588:Anticarcinogenic Agents; D002273:Carcinogens; D002788:Cholesterol Esters; D007527:Isoenzymes; D015127:9,10-Dimethyl-1,2-benzanthracene; D011493:Protein Kinase C; D009955:Ornithine Decarboxylase; C007045:cholesteryl sulfate; D013755:Tetradecanoylphorbol Acetate